reports
Galapagos NV: 1 director
A director at Galapagos NV bought 251,911 shares at 30.430USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
- Jacob Mekhael
- Martial Descoutures
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
Galapagos Uneventful 1H25 results, updates to come with 3Q25 results
Galapagos reported uneventful 1H25 results with € 3.1b in cash, though no FY25 cash burn guidance was provided (previously € 175-225m) and an update is expected with the 3Q25 results. In the pipeline, strategic alternatives continue to be explored for the cell therapy business and more information is expected with the 3Q25 results. € 37 TP maintained, though we update our rating to Accumulate (from Buy) given the absence of near-term triggers.
- Martial Descoutures
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executiv...
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, furth...
Galapagos versterkt managementteam met ervaren life sciences leidingge...
Galapagos versterkt managementteam met ervaren life sciences leidinggevenden om bedrijfstransformatie te versnellen Benoemt Sooin Kwon tot Chief Business Officer en Dan Grossman tot Chief Strategy Officer Beide leidinggevenden hebben een bewezen staat van dienst op het gebied van strategische uitvoering en het sluiten van deals en zullen helpen bij het stimuleren van waardecreatie op lange termijn bij Galapagos Mechelen, België; 23 juli, 2025, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de benoemingen aan van mevrouw Sooin Kwon als Chief Business Officer (CBO) e...
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos an...
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors to its Board of Directors, effective July 28, 2025. Dawn Svoronos and Jane Griffiths will replace Peter Guenter and Simon Sturge, who will step down from the Board on July 28, 20...
Galapagos verwelkomt ervaren farmaceutische leidinggevenden Dawn Svoro...
Galapagos verwelkomt ervaren farmaceutische leidinggevenden Dawn Svoronos en Jane Griffiths in haar Raad van Bestuur Nieuwe Bestuurders brengen uitgebreide commerciële, operationele en transactionele ervaring mee naar de Raad van Bestuur Mechelen, België; 23 juli 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de benoeming aan, via coöptatie, van Dawn Svoronos en Jane Griffiths, als Niet-Uitvoerende Onafhankelijke Bestuurders van de Raad van Bestuur, met ingang van 28 juli 2025. Dawn Svoronos en Jane Griffiths zullen Peter Guenter en Simon Sturge vervangen, die op...
Galapagos Reports Half-Year 2025 Financial Results and Provides Second...
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance pipeline expansion Strategic alternatives for the cell therapy business, including a potential divestiture, are being evaluated; CAR-T programs maintain positive momentum with recently presented clinical data Strong balance sheet with €3.1 billion in cash and financial investments as of June 30, 2025...
Galapagos rapporteert halfjaarcijfers 2025 en geeft een update over de...
Galapagos rapporteert halfjaarcijfers 2025 en geeft een update over de activiteiten in het tweede kwartaal De benoemingen van een nieuwe CEO, CFO en ervaren business development-leiders met bewezen ervaring in strategische transacties, versterken de positie van het bedrijf om aandeelhouderswaarde te creëren en de pijplijn uit te breiden Strategische alternatieven voor de celtherapieactiviteiten, waaronder een mogelijke desinvestering, worden geëvalueerd; de CAR-T-programma’s blijven positieve vooruitgang boeken met recent gepresenteerde klinische data Sterke balans met €3,1 miljard in gel...
Tessenderlo Group: 1 director
A director at Tessenderlo Group bought 626,596 shares at 25.140EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
IBA – Transparency Notification - Denominator
IBA – Transparency Notification - Denominator June 30th, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision: « [...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as...
IBA – Notification de Transparence - Dénominateur
IBA – Notification de Transparence - Dénominateur 30 juin 2025 Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (M.B. 12.VI.2007) (ci-après, la « Loi »). En vertu de cette disposition : « [...] l'émetteur publie le total du capital, le nombre total de titres conférant le droit de vote et de droits de vote, ainsi que, par catégorie, le nombre de titres conférant le droit de vote et de ...
- Jacob Mekhael
Galapagos Appoints Aaron Cox as new CFO
Galapagos announced the appointment of Aaron Cox as CFO, effective 7 July 2025. Most recently, he served as Executive VP and CFO at Horizon Therapeutics. Aaron replaces Thad Huston, who joined Galapagos as CFO in 2023. With plans to explore strategic options for the cell therapy business, as well as plans to utilise the €3.3b cash (as of 1Q25) to build a new pipeline through business development, Aaron's network and experience in deal making will be key to Galapagos' strategy going forward. We r...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
Galapagos benoemt Aaron Cox als Chief Financial Officer
Galapagos benoemt Aaron Cox als Chief Financial Officer Voormalig CFO van Horizon vervoegt Galapagos met diepgaande expertise in internationale bedrijfsfinanciering, fusies en overnames, bedrijfsontwikkeling en strategisch leiderschap Mechelen, België; 23 juni 2025, 07:30 CET; gereglementeerde informatie - voorwetenschap - Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de benoeming aan van de heer Aaron Cox als Chief Financial Officer, met ingang van 7 juli 2025. De heer Cox volgt de heer Thad Huston op, die tot 31 juli 2025 bij het bedrijf zal blijven om een soepele overdracht t...
Galapagos Appoints Aaron Cox as Chief Financial Officer
Galapagos Appoints Aaron Cox as Chief Financial Officer Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Aaron Cox as Chief Financial Officer, effective July 7, 2025. Mr. Cox succeeds Mr. Thad Huston, who will remain with the company through July 31, 2025, to ensure a smooth transition of responsibilities.Aaron brings more than two ...
- Jacob Mekhael
Galapagos GLPG5101 phase 1/2 r/r iNHL cohort differentiates with high ...
Galapagos presented new data from the ongoing Phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) at the International Conference on Malignant Lymphoma (ICML). Results from the r/r iNHL cohort (FL and MZL) showed a high complete response rate of 97%, higher than Yescarta's 75% CR rate (79% in FL, 75% in MZL) in the same patient population in the phase 2 (ZUMA-5) trial. Safety continues to be a differentiator with only 1 grade 3 ICANS (vs. 19% grade = 3 with Yescarta). All in all, a supportive ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.